The order calls on the US attorney general to expedite federal reclassification, creating fewer barriers for studies.

The move to Schedule III marks the greatest change to U.S. drug laws since 1970 and represents a new future for the $32 billion cannabis industry.

The order to place cannabis in the same category as Tylenol with codeine would mark the most significant change in US drug policy since 1971.